Vigabatrin‐associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex
Epilepsia · 2025
DOI: 10.1111/epi.18190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Carmen Stevering und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, University Medical Center Utrecht Brain Center, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Vigabatrin, Tuberous Sclerosis, Brain, Anticonvulsants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 7th Framework Program of the European Commission within the Large-Scale Integrating Project EPISTOP, VIRAP, Polish Ministerial funds for science.
Abstract (Originalsprache)
Objective
Previous retrospective studies have reported vigabatrin‐associated brain abnormalities on magnetic resonance imaging (VABAM), although clinical impact is unknown. We evaluated the association between vigabatrin and predefined brain magnetic resonance imaging (MRI) changes in a large homogenous tuberous sclerosis complex (TSC) cohort and assessed to what extent VABAM‐related symptoms were reported in TSC infants.
Methods
The Dutch TSC Registry and the EPISTOP cohort provided retrospective and prospective data from 80 TSC patients treated with vigabatrin (VGB) before the age of 2 years and 23 TSC patients without VGB. Twenty‐nine age‐matched non‐TSC epilepsy patients not receiving VGB were included as controls. VABAM, specified as T2/fluid‐attenuated inversion recovery hyperintensity or diffusion restriction in predefined brain areas, were examined on brain MRI before, during, and after VGB, and once in the controls (at approximately age 2 years). Additionally, the presence of VABAM accompanying symptoms was evaluated.
Results
Prevalence of VABAM in VGB‐treated TSC patients was 35.5%. VABAM‐like abnormalities were observed in 13.5% of all patients without VGB. VGB was significantly associated with VABAM (risk ratio [RR] = 3.57, 95% confidence interval [CI] = 1.43–6.39), whereas TSC and refractory epilepsy were not. In all 13 VGB‐treated patients with VABAM for whom posttreatment MRIs were available, VABAM entirely resolved after VGB discontinuation. The prevalence of symptoms was 11.7% in patients with VABAM or VABAM‐like MRI abnormalities and 4.3% in those without, implicating no significant association (RR = 2.76, 95% CI = .68–8.77). Significance VABAM are common in VGB‐treated TSC infants; however, VABAM‐like abnormalities also occurred in children without either VGB or TSC. The cause of these MRI changes is unknown. Possible contributing factors are abnormal myelination, underlying etiology, recurrent seizures, and other antiseizure medication. Furthermore, the presence of VABAM (or VABAM‐like abnormalities) did not appear to be associated with clinical symptoms. This study confirms that the well‐known antiseizure effects of VGB outweigh the risk of VABAM and related symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Neurology, University Medical Center Utrecht Brain Center, Utrecht, The Netherlands.
- Department of Radiology, University Medical Center, Utrecht, The Netherlands.
- Research Department, Department of Neurology and Epileptology, Children's Memorial Health Institute, Warsaw, Poland.
- Image Sciences Institute, Division Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Rome, Italy.
ORCID-Profile: Carmen Stevering, Maarten Lequin, Kinga Szczepaniak, Krzysztof Sadowski, Saba Ishrat, Alberto De Luca, Alexander Leemans, Willem Otte, David J Kwiatkowski, Paolo Curatolo, Bernhard Weschke, Kate Riney, Martha Feucht, Pavel Krsek, Rima Nabbout, Anna Jansen, Konrad Wojdan, Kamil Sijko, Jagoda Glowacka-Walas, Julita Borkowska, Dorota Domanska-Pakiela, Romina Moavero, Christoph Hertzberg, Hanna Hulshof, Theresa Scholl, Bořivoj Petrák, Miroslav Maminak, Eleonora Aronica, Jessie De Ridder, Lieven Lagae, Sergiusz Jozwiak, Katarzyna Kotulska, Kees Braun, Floor Jansen
Förderung
- 7th Framework Program of the European Commission within the Large-Scale Integrating Project EPISTOP
- VIRAP
- Polish Ministerial funds for science
- Medical Research Agency, Poland, and a statutory
- Agencja Badań Medycznych
Zitieren
APA
Stevering, C., Lequin, M., Szczepaniak, K., Sadowski, K., Ishrat, S., De Luca, A., Leemans, A., Otte, W., Kwiatkowski, D. J., Curatolo, P., Weschke, B., Riney, K., Feucht, M., Krsek, P., Nabbout, R., Jansen, A., Wojdan, K., Sijko, K., Glowacka-Walas, J., …, & Jansen, F. (2025). Vigabatrin‐associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex. Epilepsia. https://doi.org/10.1111/epi.18190
Vancouver
Stevering C, Lequin M, Szczepaniak K, Sadowski K, Ishrat S, De Luca A, et al. Vigabatrin‐associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex. Epilepsia. 2025. doi:10.1111/epi.18190
BibTeX
@article{Stevering2025,
author = {Stevering, Carmen and Lequin, Maarten and Szczepaniak, Kinga and Sadowski, Krzysztof and Ishrat, Saba and De Luca, Alberto and Leemans, Alexander and Otte, Willem and Kwiatkowski, David J and Curatolo, Paolo and Weschke, Bernhard and Riney, Kate and Feucht, Martha and Krsek, Pavel and Nabbout, Rima and Jansen, Anna and Wojdan, Konrad and Sijko, Kamil and Glowacka-Walas, Jagoda and Borkowska, Julita and Domanska-Pakiela, Dorota and Moavero, Romina and Hertzberg, Christoph and Hulshof, Hanna and Scholl, Theresa and Petrák, Bořivoj and Maminak, Miroslav and Aronica, Eleonora and De Ridder, Jessie and Lagae, Lieven and Jozwiak, Sergiusz and Kotulska, Katarzyna and Braun, Kees and Jansen, Floor},
title = {Vigabatrin‐associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex},
journal = {Epilepsia},
year = {2025},
doi = {10.1111/epi.18190}
}
EUVIMED